New drug BL-M17D1 enters first human trial for Hard-to-Treat HER2 cancers
NCT ID NCT06500052
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a new drug called BL-M17D1 in 20 people with advanced HER2-positive gastrointestinal cancers (like stomach, pancreas, or colon cancer) or other solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors. Participants receive the drug by IV every 3 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-M17D1 (a drug given by IV infusion every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced HER2-positive gastrointestinal and other solid tumors.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is too soon to know if it will work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug shield nerves from Chemotherapy's side effects?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk